CoChat

Gut Microbiota and Tacrolimus Dosing in Kidney Transplantation

Open access

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

Tacrolimus dosing to establish therapeutic levels in recipients of organ transplants is a challenging task because of much interpatient and intrapatient variability in drug absorption, metabolism, and disposition. In view of the reported impact of gut microbial species on drug metabolism, we investigated the relationship between the gut microbiota and tacrolimus dosing requirements in this pilot study of adult kidney transplant recipients. Serial fecal specimens were collected during the first month of transplantation from 19 kidney transplant recipients who either required a 50% increase from initial tacrolimus dosing during the first month of transplantation (Dose Escalation Group, n=5) or did not require such an increase (Dose Stable Group, n=14). We characterized bacterial composition in the fecal specimens by deep sequencing of the PCR amplified 16S rRNA V4-V5 region and we investigated the hypothesis that gut microbial composition is associated with tacrolimus dosing requirements. Initial tacrolimus dosing was similar in the Dose Escalation Group and in the Stable Group (4.2 ± 1.1 mg/day vs. 3.8 ± 0.8 mg/day, respectively, P=0.61, two-way between-group ANOVA using contrasts) but became higher in the Dose Escalation Group than in the Dose Stable Group by the end of the first transplantation month (9.6 ± 2.4 mg/day vs. 3.3 ± 1.5 mg/day, respectively, P<0.001). Our systematic characterization of the gut microbial composition identified that fecal Faecalibacterium prausnitzii abundance in the first week of transplantation was 11.8% in the Dose Escalation Group and 0.8% in the Dose Stable Group (P=0.002, Wilcoxon Rank Sum test, P<0.05 after Benjamini-Hochberg correction for multiple hypotheses). Fecal Faecalibacterium prausnitzii abundance in the first week of transplantation was positively correlated with future tacrolimus dosing at 1 month (R=0.57, P=0.01) and had a coefficient ± standard error of 1.0 ± 0.6 (P=0.08) after multivariable linear regression. Our novel observations may help further explain inter-individual differences in tacrolimus dosing to achieve therapeutic levels.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0122399

Cites

43 of 44 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Tacrolimus Trough Levels and Tacrolimus Dosing in the Kidney Transplant Cohort. A) Tacrolimus troughs are shown over the course of the first month. On the x-axis is the day after kidney transplantation and on the y-axis is the mean tacrolimus trough of the group (ng/mL) corresponding to the day on the x-axis. The Dose Escalation Group is represented by the red line with corresponding standard deviation bars and the Dose Stable Group is represented by the green line with corresponding standard deviation bars. P values at each time point were calculated using a two-way between-group ANOVA using contrasts to evaluate the two groups at each time point and is listed above each time point. B) Tacrolimus dosing is shown over the course of the first month. On the x-axis is the day after kidney transplantation and on the y-axis is the mean tacrolimus dosing of the group (mg/day) corresponding to the day on the x-axis. The Dose Escalation Group is represented by the red line with corresponding standard deviation bars and the Dose Stable Group is represented by the green line with corresponding standard deviation bars. P values at each time point were calculated using a two-way between-group ANOVA using contrasts to evaluate the two groups at each time point and is listed above each time point.
Fig 1 Tacrolimus Trough Levels and Tacrolimus Dosing in the Kidney Transplant Cohort. A) Tacrolimus troughs are shown over the course of the first month. On the x-axis is the day after kidney transplantation and on the y-axis is the mean tacrolimus trough of the group (ng/mL) corresponding to the day on the x-axis. The Dose Escalation Group is represented by the red line with corresponding standard deviation bars and the Dose Stable Group is represented by the green line with corresponding standard deviation bars. P values at each time point were calculated using a two-way between-group ANOVA using contrasts to evaluate the two groups at each time point and is listed above each time point. B) Tacrolimus dosing is shown over the course of the first month. On the x-axis is the day after kidney transplantation and on the y-axis is the mean tacrolimus dosing of the group (mg/day) corresponding to the day on the x-axis. The Dose Escalation Group is represented by the red line with corresponding standard deviation bars and the Dose Stable Group is represented by the green line with corresponding standard deviation bars. P values at each time point were calculated using a two-way between-group ANOVA using contrasts to evaluate the two groups at each time point and is listed above each time point.CC BY · PubMed Central
Fig 2 Gut Microbial Diversity During the First Month of Kidney Transplantation. Shannon diversity index is represented over time in all 19 kidney transplant recipients. On the x-axis is the day after kidney transplantation and on the y axis is the Shannon diversity index. Each individual black circle represents a fecal specimen at the time point indicated on the x-axis. The blue line represents a locally estimated scatterplot-smoothed (LOESS) calibration curve with the grey areas representing 95% confidence intervals. As shown, the Shannon diversity index was relatively stable in the study cohort during the first month of transplantation.
Fig 2 Gut Microbial Diversity During the First Month of Kidney Transplantation. Shannon diversity index is represented over time in all 19 kidney transplant recipients. On the x-axis is the day after kidney transplantation and on the y axis is the Shannon diversity index. Each individual black circle represents a fecal specimen at the time point indicated on the x-axis. The blue line represents a locally estimated scatterplot-smoothed (LOESS) calibration curve with the grey areas representing 95% confidence intervals. As shown, the Shannon diversity index was relatively stable in the study cohort during the first month of transplantation.CC BY · PubMed Central
Fig 3 Most Abundant Phyla in the Kidney Transplant Cohort. The relative fecal abundances of the most common phyla are shown for each of the 51 fecal specimens. On the x-axis are individual fecal specimens from the study cohort and on the y-axis is the relative abundance of a taxon. Each bar represents an individual fecal specimen with the color representing the specific phylum indicated in the legend.
Fig 3 Most Abundant Phyla in the Kidney Transplant Cohort. The relative fecal abundances of the most common phyla are shown for each of the 51 fecal specimens. On the x-axis are individual fecal specimens from the study cohort and on the y-axis is the relative abundance of a taxon. Each bar represents an individual fecal specimen with the color representing the specific phylum indicated in the legend.CC BY · PubMed Central
Fig 4 Differences in the Gut Microbiota Between the Tacrolimus Groups. The principal coordinate analyses of the week 1 fecal specimens from the 19 kidney graft recipients are shown. The first two axes of the principal coordinate analysis are represented with principal coordinate axis 1 on the y-axis (10.7% variability) and principal coordinate axis 2 on the x-axis (7.2% variability). The individual red points represent the 5 post-transplantation week 1 fecal specimens from the 5 subjects in the Dose Escalation Group and the individual green points represent the 14 post-transplantation week 1 fecal specimens from the 14 subjects in the Dose Stable Group.
Fig 4 Differences in the Gut Microbiota Between the Tacrolimus Groups. The principal coordinate analyses of the week 1 fecal specimens from the 19 kidney graft recipients are shown. The first two axes of the principal coordinate analysis are represented with principal coordinate axis 1 on the y-axis (10.7% variability) and principal coordinate axis 2 on the x-axis (7.2% variability). The individual red points represent the 5 post-transplantation week 1 fecal specimens from the 5 subjects in the Dose Escalation Group and the individual green points represent the 14 post-transplantation week 1 fecal specimens from the 14 subjects in the Dose Stable Group.CC BY · PubMed Central
Fig 5 Fecal Faecalibacterium prausnitzii Abundance by Tacrolimus Dosing Groups. Each individual subject is represented on the x-axis and the week 1 fecal Faecalibacterium prausnitzii abundance is represented on the y-axis. Individual subjects in the Dose Stable Group are represented in green (the 14 subjects on the left) and individuals subjects in the Dose Escalation Group are represented in red (the 5 subjects on the right). The Dose Escalation Group had a significantly higher Faecalibacterium prausnitzii proportion than the Dose Stable Group (11.8% vs. 0.8%, respectively, uncorrected P = 0.002, Wilcoxon Rank-Sum test, P<0.05 after Benjamini-Hochberg correction for multiple hypotheses).
Fig 5 Fecal Faecalibacterium prausnitzii Abundance by Tacrolimus Dosing Groups. Each individual subject is represented on the x-axis and the week 1 fecal Faecalibacterium prausnitzii abundance is represented on the y-axis. Individual subjects in the Dose Stable Group are represented in green (the 14 subjects on the left) and individuals subjects in the Dose Escalation Group are represented in red (the 5 subjects on the right). The Dose Escalation Group had a significantly higher Faecalibacterium prausnitzii proportion than the Dose Stable Group (11.8% vs. 0.8%, respectively, uncorrected P = 0.002, Wilcoxon Rank-Sum test, P<0.05 after Benjamini-Hochberg correction for multiple hypotheses).CC BY · PubMed Central
Fig 6 Correlations with Tacrolimus Dosing at 1 Month. A) Fecal Faecalibacterium prausnitzii abundance at 1 week post-transplantation is associated with tacrolimus dosing at 1 month. On the x-axis is the log transformed fecal week 1 Faecalibacterium prausnitzii abundance and on the y-axis is the corresponding subject’s tacrolimus dosing at 1 month (mg/day). There was a positive correlation between the log-transformed fecal week 1 Faecalibacterium prausnitzii abundance and tacrolimus dosing at 1 month (Pearson R = 0.57, P = 0.01). B) Age at transplantation is negatively associated with tacrolimus dosing at 1 month. On the x-axis is the age at transplantation and on the y-axis is the corresponding subject’s tacrolimus dosing at 1 month (mg/day). There was a negative correlation between age and tacrolimus dosing at 1 month (Pearson R = -0.55, P = 0.02). C) Post-transplantation week 1 hemoglobin concentration is negatively associated with tacrolimus dosing at 1 month. On the x-axis is the week 1 hemoglobin concentration and on the y-axis is the corresponding subject’s tacrolimus dosing at 1 month (mg/day). There was a negative correlation between week 1 hemoglobin concentration and tacrolimus dosing at 1 month (Pearson R = -0.50, P = 0.03).
Fig 6 Correlations with Tacrolimus Dosing at 1 Month. A) Fecal Faecalibacterium prausnitzii abundance at 1 week post-transplantation is associated with tacrolimus dosing at 1 month. On the x-axis is the log transformed fecal week 1 Faecalibacterium prausnitzii abundance and on the y-axis is the corresponding subject’s tacrolimus dosing at 1 month (mg/day). There was a positive correlation between the log-transformed fecal week 1 Faecalibacterium prausnitzii abundance and tacrolimus dosing at 1 month (Pearson R = 0.57, P = 0.01). B) Age at transplantation is negatively associated with tacrolimus dosing at 1 month. On the x-axis is the age at transplantation and on the y-axis is the corresponding subject’s tacrolimus dosing at 1 month (mg/day). There was a negative correlation between age and tacrolimus dosing at 1 month (Pearson R = -0.55, P = 0.02). C) Post-transplantation week 1 hemoglobin concentration is negatively associated with tacrolimus dosing at 1 month. On the x-axis is the week 1 hemoglobin concentration and on the y-axis is the corresponding subject’s tacrolimus dosing at 1 month (mg/day). There was a negative correlation between week 1 hemoglobin concentration and tacrolimus dosing at 1 month (Pearson R = -0.50, P = 0.03).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 234

Metadata

Authors
Lee, J. R., Muthukumar, T., Dadhania, D., Taur, Y., Jenq, R. R., Toussaint, N. C., Ling, L., Pamer, E., & Suthanthiran, M.
Affiliations
  • NewYork–Presbyterian Hospital (US)
  • Memorial Sloan Kettering Cancer Center (US)
Corresponding author
Lee, John R.
Venue
PLOS ONE
Published
2015-03-27
Volume
10
Issue
3
Pages
e0122399
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2073075095
Cited by
211
References
43
Citations by year
2026: 19 · 2025: 22 · 2024: 23 · 2023: 27 · 2022: 18 · 2021: 27 · 2020: 17 · 2019: 16 · 2018: 14 · 2017: 10 · 2016: 13 · 2015: 5
FWCI
11.44
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • National Institutes of Health (KL2TR000458, UL1TR000457, UL1TR002384)
  • National Cancer Institute (P30CA008748)
  • National Institute of Allergy and Infectious Diseases (R37AI051652)
  • National Institute of Diabetes and Digestive and Kidney Diseases (K08DK087824)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
gut microbiota, tacrolimus dosing, kidney transplantation, Faecalibacterium prausnitzii, dose escalation, fecal microbiota, interpatient variability, drug metabolism, immunosuppression, therapeutic drug monitoring
MeSH terms
Gastrointestinal Microbiome, Adult, Aged, Bacteria, Dose-Response Relationship, Drug, Feces, Female, Graft Rejection, Humans, Male, Middle Aged, RNA, Ribosomal, 16S, Kidney Transplantation, Tacrolimus, Transplant Recipients

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.